Timir Paul, C3 2019 – Embolic Protection Devices and Coronary Saphenous Vein Bypass Grafts
We spoke to Dr Timir Paul (Cardiovascular Research, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA) about the update in guidelines for embolic protection devices and coronary saphenous vein bypass grafts, as well as his observations on the relative effectiveness of drug-eluting stents compared with bare-metal stents.
Speaker’s Disclosures: Timir Paul has nothing to declare in relation to this video interview.
Questions:
1. Recently, the role of embolic protection devices’ coronary saphenous vein bypass grafts has been re-examined in guidelines; what has changed and what advice would you provide to physicians on how to incorporate this guidance into practice? (0:04)
2. What are your observations on the recent studies assessing relative effectiveness of drug-eluting stents compared with bare-metal stents in patients undergoing saphenous vein graft interventions? (1:57)
3. What are your key highlights from your presentations at this year’s C3 congress? (3:45)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with C3 at the 2019 annual meeting in Orlando, Florida, June 2019.